Exome Asset Management LLC Has $4.86 Million Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

Exome Asset Management LLC decreased its position in TG Therapeutics, Inc. (NASDAQ:TGTX) by 17.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 207,627 shares of the biopharmaceutical company’s stock after selling 43,973 shares during the quarter. TG Therapeutics makes up approximately 3.2% of Exome Asset Management LLC’s portfolio, making the stock its 5th largest position. Exome Asset Management LLC owned about 0.13% of TG Therapeutics worth $4,856,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. NBC Securities Inc. grew its position in TG Therapeutics by 58.9% in the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 485 shares in the last quarter. Ashton Thomas Private Wealth LLC bought a new position in shares of TG Therapeutics in the second quarter valued at approximately $35,000. Blue Trust Inc. grew its holdings in shares of TG Therapeutics by 127.3% in the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 849 shares in the last quarter. ORG Wealth Partners LLC purchased a new stake in shares of TG Therapeutics during the third quarter valued at approximately $53,000. Finally, Values First Advisors Inc. bought a new stake in TG Therapeutics during the third quarter worth $58,000. Hedge funds and other institutional investors own 58.58% of the company’s stock.

TG Therapeutics Trading Up 4.3 %

Shares of TG Therapeutics stock opened at $32.02 on Friday. The company’s 50-day moving average price is $28.56 and its 200-day moving average price is $23.35. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. TG Therapeutics, Inc. has a 12-month low of $12.84 and a 12-month high of $36.84. The company has a market cap of $4.98 billion, a price-to-earnings ratio of -320.17 and a beta of 2.25.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.01). The firm had revenue of $83.90 million during the quarter, compared to the consensus estimate of $81.68 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company’s revenue for the quarter was down 49.4% compared to the same quarter last year. During the same period in the previous year, the company posted $0.73 EPS. On average, equities analysts expect that TG Therapeutics, Inc. will post 0.17 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Sagar Lonial sold 5,000 shares of the stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $30.44, for a total transaction of $152,200.00. Following the transaction, the director now directly owns 100,195 shares in the company, valued at approximately $3,049,935.80. This represents a 4.75 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 10.50% of the company’s stock.

Wall Street Analysts Forecast Growth

TGTX has been the topic of a number of recent analyst reports. The Goldman Sachs Group lifted their target price on TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. HC Wainwright raised their price target on shares of TG Therapeutics from $49.00 to $55.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. JPMorgan Chase & Co. increased their price objective on TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a report on Monday, November 25th. TD Cowen assumed coverage on TG Therapeutics in a research note on Tuesday, October 29th. They issued a “buy” rating and a $50.00 target price on the stock. Finally, StockNews.com upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, TG Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $40.67.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.